Company Profile

Nano Biotherapeutics Inc
Profile last edited on: 7/10/20      CAGE: 7QAZ6      UEI: E97JBYKPBNW5

Business Identifier: Drug platform to treate acute and chronic tissue inflammation and tissue injury in the heart and lungs.
Year Founded
2016
First Award
2015
Latest Award
2019
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2201 West Campbell Park Drive Suite 326
Chicago, IL 60612
   (877) 331-6168
   info@nanobiotherapeutics.com
   nanobiotherapeutics.com
Location: Single
Congr. District: 07
County: Cook

Public Profile

Nano Biotherapeutics Inc is developing a drug platform to treat acute and chronic inflammation and tissue injury in the heart and lungs using albumin nanoparticle mediated drug delivery. The nano drug platform is based on albumin, a natural protein, and the firm's nanoparticle can entrap small hydophobic drugs.The nanoparticel is loaded with an anti-inflammatory drug to target activated neutrophils, which accumulates at the site of injury. Then, the released drug suppresses inflammation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $3,387,167
Project Title: HLS13-13 Albumin Nanoparticle Based Technology to Treat Ards

Key People / Management

  Asrar B Malik -- CEO

  Prasad V S Kantet

  Andrew Stuart -- Senior Scientist

Company News

There are no news available.